A DFT study on non-enzymatic degradations of anti-tuberculosis drug isoniazid
- PMID: 37615715
- DOI: 10.1007/s00894-023-05700-7
A DFT study on non-enzymatic degradations of anti-tuberculosis drug isoniazid
Abstract
Context: Isoniazid (INH) is one of the medications most used for tuberculosis (TB) treatment. However, long-term continuous therapy can cause hepatotoxicity and peripheral neuritis. The degradation of INH is an important aspect of the research in the field of drug stability as well as drug formulation for controlling release. It is thought that tautomerization, hydrolysis as well as nucleophilic substitutions can cause decrease in INH as non-enzymatic degradation. Therefore, it is crucial to understand the mechanisms and energies of the major reactions in order to provide reference for future drug formulation and application. This study is an effort to understand the kinetic and thermodynamic properties of the non-enzymatic degradation reactions. The chemical reaction phenomena are investigated using the density functional theory (DFT) method. This study shows that major degradation of INH can be done via tautomerization followed by hydrolysis. The general trends in nucleophilic degradation presented here are consistent with experimental pKa of nucleophiles.
Methods: All DFT calculations were performed using the Gaussian Software Packages (Gaussian 09 revision B.01 and GaussView 5.0.8). MOLEKEL 4.3 software was utilized to visualize the molecular graphics of all relevant species. The optimized molecular geometries were calculated using B3LYP/6-311 + G(d,p) level in the gas phase. The IEF-PCM/B3LYP/6-311 + G(d,p) level was selected for single-point and frequency calculations in aqueous media.
Keywords: Biodegradation; DFT; Degradation; Hydrolysis; INH; Isoniazid; Nucleophile; Pharmaceutical co-crystal; TB; Tautomers; Tuberculosis.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
DFT study on the effect of proximal residues on the Mycobacterium tuberculosis catalase-peroxidase (katG) heme compound I intermediate and its bonding interaction with isoniazid.Phys Chem Chem Phys. 2019 Jul 31;21(30):16515-16525. doi: 10.1039/c9cp01465a. Phys Chem Chem Phys. 2019. PMID: 31298238
-
Unravelling performance of honeycomb structures as drug delivery systems for the isoniazid drug using DFT-D3 correction dispersion and molecular dynamic simulations.Phys Chem Chem Phys. 2024 May 8;26(18):14018-14036. doi: 10.1039/d3cp05457h. Phys Chem Chem Phys. 2024. PMID: 38683598
-
Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis.Curr Drug Metab. 2017;18(11):1030-1039. doi: 10.2174/1389200218666171031121905. Curr Drug Metab. 2017. PMID: 29086682 Review.
-
Mechanisms of isoniazid release from poly(d,l-lactide-co-glycolide) matrices prepared by dry-mixing and low density polymeric foam methods.J Pharm Sci. 1996 Jul;85(7):706-13. doi: 10.1021/js950521y. J Pharm Sci. 1996. PMID: 8818994
-
Isoniazid derivatives and their anti-tubercular activity.Eur J Med Chem. 2017 Jun 16;133:255-267. doi: 10.1016/j.ejmech.2017.04.002. Epub 2017 Apr 3. Eur J Med Chem. 2017. PMID: 28390957 Review.
References
-
- Carazo E, Borrego-Sánchez A, García-Villén F, Sánchez-Espejo R, Viseras C, Cerezo P, Aguzzi C (2018) Appl Clay Sci 160:180–185
-
- Adeleke OA, Tsai PC, Karry KM, Monama NO, Michniak-Kohn BB (2018) Int J Pharm 547:347–359 - PubMed
-
- World Health Organization (2022) WHO Global Tuberculosis Report 2022; World Health Organization: Geneva, Switzerland
-
- Raviglione MC, Sinder DES Jr, Kochi A (1995) JAMA 273:220–226 - PubMed
-
- Samad A, Sultana Y, Khar RK, Aqil M, Chuttani K, Mishra AK (2008) Drug Discov Ther 2(2):108–114 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources